<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570465</url>
  </required_header>
  <id_info>
    <org_study_id>AML1411</org_study_id>
    <nct_id>NCT01570465</nct_id>
  </id_info>
  <brief_title>Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients</brief_title>
  <acronym>AML1411</acronym>
  <official_title>Prospective Survey on Severe Infections During a Multicenter Study of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients receiving induction, consolidation and salvage chemotherapy, and autologous or
      allogeneic stem cell transplantation according to a strategy defined in the GIMEMA AML1310
      protocol will be prospectively monitored for SI (bacteremia, invasive mycoses, other
      microbiologically documented bacterial infections, pneumonia, other invasive tissue
      infections and viral diseases) during each chemotherapy and transplant and the impact of
      these infections on survival will be evaluated until 24 months from the diagnosis of AML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of AML patients during chemotherapy and SCT is frequently complicated by SI which
      may represent an obstacle to the antileukemic chemotherapy and transplant program.
      Antimicrobial prophylaxis, diagnostic approaches and antimicrobial therapy should be adapted
      to the infectious risk of the leukemic population. A crucial problem in the definition of
      these strategies is represented by the continuous change in the epidemiological patterns of
      infections as a result of the modification of risk factors in the leukemic population and of
      the global epidemiology of hospital and community acquired infections. In particular, the
      emergence of antibiotic resistant pathogens, particularly among gram negative bacteria,
      represents a serious problem which dramatically impacts on the antibacterial prophylaxis and
      treatments choices. A continuous epidemiology survey is required in order to better define
      proper prevention, diagnostic and treatment approaches. A common problem in the infections
      control in immunocompromised populations is represented by a late epidemiological
      consciousness. In particular, when new antileukemic strategies are implemented any change in
      the infectious epidemiology is frequently evidenced later retrospectively, but retrospective
      studies suffer of several drawbacks in the timely and proper collection of data.

      The aim of the AML1310 GIMEMA protocol is to prospectively evaluate in a large population of
      newly diagnosed young AML patients the effect of a risk-adapted, MDR directed antileukemic
      strategy which includes chemotherapy and SCT. The objective of the trial is to evaluate the
      treatment strategy in terms of OS at 24 months and secondary objectives include the response
      rates and outcome according to clinical and biological characteristics at baseline and along
      the antileukemic treatment. A further secondary objective of the AML1310 study is the
      evaluation of the quality of life.

      A prospective, longitudinal survey of infectious complications occurring in patients enrolled
      in the AML1310 study along the entire antileukemic program, as an ancillary observational
      study, may be a useful tool to evaluate in real-time the epidemiological patterns of
      infections, their impact on the OS, on the antileukemic treatment schedule, and on the
      quality of life. First, it may allow to assess whether the various types of SI, in addition
      to well known clinical and leukemia-related prognostic variables, are actually independent
      prognostic factors for the long-term outcome of AML patients. Second, the results of this
      survey may offer precious indications for the timely update of the prophylaxis , diagnosis
      and treatment strategies of infections in AML patients undergoing a modern antileukemic
      program. The advances in the treatment of AML resulting from the AML1310 study may be further
      enriched by the epidemiological consciousness derived by a parallel survey of the infectious
      complications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic role on overall survival</measure>
    <time_frame>At four years from study entry.</time_frame>
    <description>At 24 months of each type of Severe Infection (SI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of incidence of SI.</measure>
    <time_frame>At four years from study entry</time_frame>
    <description>Rate of incidence of SI during chemotherapy, transplantation procedures, and follow up of patients enrolled in the GIMEMA study AML1310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of SI on the respect of the step by step time treatment.</measure>
    <time_frame>At four years from study entry.</time_frame>
    <description>To estimate the impact of SI on the respect of the step by step time treatment along the GIMEMA study AML1310. SI will be considered among the causes of delay or discontinuation or change of the leukemia treatment schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors and prognostic factors of each type of SI.</measure>
    <time_frame>At 4 years from study entry</time_frame>
    <description>To estimate the risk factors and prognostic factors of each type of SI according to baseline leukemia risk (low, intermediate and high risk) as defined in the AML1310 protocol;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and attributable mortality.</measure>
    <time_frame>At 4 years from study entry.</time_frame>
    <description>To estimate the overall and attributable mortality at 3 months from the onset of the SI. Attributable mortality was defined as progressive organ failure involving the organ(s) in which SI was diagnosed and the absence of other morbid conditions thought, by the attending physician or pathologist, to have contributed to death;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of the in vitro susceptibility pattern to antimicrobials of bacteria causing SI with particular attention to the emerging resistances in gram negative bacteria (ESBL, KPC MDR);</measure>
    <time_frame>At 4 years from study entry</time_frame>
    <description>To evaluate the rate of the in vitro susceptibility pattern to antimicrobials of bacteria causing SI with particular attention to the emerging resistances in gram negative bacteria (ESBL, KPC MDR);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients receiving each type of antibacterial and antifungal prophylaxis strategies employed during the various antileukemic treatments;</measure>
    <time_frame>At 4 years from study entry</time_frame>
    <description>To evaluate the rate of patients receiving each type of antibacterial and antifungal prophylaxis strategies employed during the various antileukemic treatments;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of antibacterial and antifungal administered treatments guided either empirically or by clinical and microbiological evidences;</measure>
    <time_frame>At 4 years from study entry</time_frame>
    <description>To estimate the rate of antibacterial and antifungal administered treatments guided either empirically or by clinical and microbiological evidences;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of SI in the quality of life.</measure>
    <time_frame>At 4 years from study entry</time_frame>
    <description>To evaluate the impact of SI in the quality of life.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">237</enrollment>
  <condition>AML</condition>
  <condition>Adult</condition>
  <arm_group>
    <arm_group_label>All patients enrolled in the GIMEMA AML1310 study.</arm_group_label>
    <description>All patients enrolled in the GIMEMA AML1310 study;
Signed written informed consent according to ICH/EU/GCP and national local laws.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.</description>
    <arm_group_label>All patients enrolled in the GIMEMA AML1310 study.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving induction, consolidation and salvage chemotherapy, and autologous or
        allogeneic stem cell transplantation according to a strategy defined in the GIMEMA AML1310
        protocol will be prospectively monitored for SI (bacteremia, invasive mycoses, other
        microbiologically documented bacterial infections, pneumonia, other invasive tissue
        infections and viral diseases) during each chemotherapy and transplant and the impact of
        these infections on survival will be evaluated until 24 months from the diagnosis of AML.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients enrolled in the GIMEMA AML1310 study;

          -  Signed written informed consent according to ICH/EU/GCP and national local laws.

        Exclusion Criteria:

          -  Patients not eligible for the GIMEMA AML1310 study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriano VENDITTI, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Tor Vergata di Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola FAZI, Dr.</last_name>
    <phone>+39 0670390521</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico CREA</last_name>
    <phone>+39 0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U.O. di Medicina Interna - ASUR Marche 8 - Ospedale Civile</name>
      <address>
        <city>Civitanova Marche</city>
        <state>Ancona</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riccardo Centurioni, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Riccardo Centurioni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milena Mirabile, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorella De Paoli</last_name>
    </contact>
    <investigator>
      <last_name>Lorella De Paoli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flavia Salvi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Offidani, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Offidani, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debora Capelli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giogina Specchia, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giogina Specchia, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Domenico Pastore, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Martinelli, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Martinelli, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Clissa, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Quarta</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Quarta, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacomo Loseto, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Storti, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Storti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristiana Gasbarrino, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Onco-Ematologia - A.O. S.Anna e S.Sebastiano</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Abbadessa</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Abbadessa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Camera, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Di Raimondo</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Calogero Vetro, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Molica</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Molica, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Grazia Kropp, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia C.T.M.O. Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Lanza, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Lanza, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Domenico Pastore, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia e Fisiopatologia delle Emostasi - Azienda Ospedaliera - Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cuneo</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Cuneo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Cavazzini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvana Franca, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Silvana Franca, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celestino Ferrandina, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale &quot;Santa Maria Goretti&quot;</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo De Blasio, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Angelo De Blasio, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Centra, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelina Dargenio, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Brugiatelli, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Maura Brugiatelli, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piero Terrizzi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda ' Ca Granda'</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Marbello, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Laura Marbello, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Mancini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agostino Cortelezzi</last_name>
    </contact>
    <investigator>
      <last_name>Agostino Cortelezzi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Fracchiolla, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese - Dipartimento di Oncoematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Luppi</last_name>
    </contact>
    <investigator>
      <last_name>Mario Luppi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Morselli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Pane, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Pane, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Cerciello, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mastrullo</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Mastrullo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosaria Villa, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nocera Inferiore U.O. Medicina Interna Ematologia ed Oncologia P.O. Umberto I</name>
      <address>
        <city>Nocera Inferiore</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Maria D'Arco</last_name>
    </contact>
    <investigator>
      <last_name>Alfonso Maria D'Arco, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catello Califano, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Saglio, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Saglio, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco De Gobbi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncoematologia -plesso ospedaliero &quot;A. Tortora&quot; di Pagani</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catello Califano</last_name>
    </contact>
    <investigator>
      <last_name>Catello Califano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Fabbiano, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Fabbiano, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Caramatti, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Cecilia Caramatti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Rosetti, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Visani</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Visani</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Isidori</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Fioritoni, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Fioritoni, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prassede Salutari, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Vallisa, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Vallisa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Trabacchi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Petrini</last_name>
    </contact>
    <investigator>
      <last_name>Mario Petrini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Pizzuti, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Michele Pizzuti, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nunzio Filardi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Nobile</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Nobile, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Ronco, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Merli, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Merli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annalisa Imovili, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. &quot;Sant'Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Ferrari, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Antonella Ferrari, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Veggir, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Pacilli</last_name>
    </contact>
    <investigator>
      <last_name>Leonardo Pacilli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Proia, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano VENDITTI, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Adriano VENDITTI, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corrado GIRMENIA, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roma Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana Annino, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Luciana Annino, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Chierichini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Spadea, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Spadea, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariella D'Andrea, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo De Fabritiis, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Paolo De Fabritiis, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Sica, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Simona Sica, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Medicina Trasfusionale e Cellule Staminali Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Pacilli</last_name>
    </contact>
    <investigator>
      <last_name>Leonardo Pacilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorella Melillo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Serv. di Ematologia Ist. di Ematologia ed Endocrinologia</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Longinotti, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Longinotti, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Fozza, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda U.L.S.S.9 - U.O. di Ematologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Gherlinzoni, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Filippo Gherlinzoni, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Gottardi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia - Azienda Ospedaliera - Pia Fondazione di Culto e di Religione Card. G.Panico</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppina Greco, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Candoni, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Anna Candoni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Simeone, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation Website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>adult</keyword>
  <keyword>AML1310 GIMEMA study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

